Metal-Based Drugs

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 November 2017)

Special Issue Editor

Faculté de Pharmacie, Université Libre de Bruxelles, Campus Plaine CP 205/5, 1050 Brussels, Belgium
Interests: medicinal chemistry; organic synthesis; asymmetric synthesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metals are known and used by human beings since time immemorial. Logically, they have been administered to ill people to treat a large number of health disorders, most of the times empirically. This led to some unexpected successes, discovered by chance (for instance, the use of mercury or lead against infection, or arsenic as anticancer treatment). With the development of organic chemistry and the pharmaceutical industry, interest for metals in human health has rather waned until the 1970s with the marketing of platinum anticancer drugs, gadolinium-containing contrast agents and strontium salts against osteoporosis.

The purpose of the present Special Issue is to present the latest advances in the field of metals used in medicine, classified following their pharmacological applications in several diseases, such as cancers, diabetes, osteoporosis, and as diagnostic agents. The emphasis will be put on the most promising drug candidates in each pharmacological class.

Dr. Francois Dufrasne
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metal
  • complexes
  • salts
  • pharmacology
  • drugs
  • organometallics

Related Special Issues

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

1376 KiB  
Article
Biotinylated Chlorin and Its Zinc and Indium Complexes: Synthesis and In Vitro Biological Evaluation for Photodynamic Therapy
Pharmaceuticals 2017, 10(2), 41; https://doi.org/10.3390/ph10020041 - 15 Apr 2017
Cited by 14 | Viewed by 4405
Abstract
The synthesis and characterization of biotinylated chlorin photosensitizer and the corresponding zinc and indium complexes are described for potential applications in photodynamic therapy (PDT) for cancer. Phototoxicity of the biotin-chlorin conjugate and the metallated complexes was determined in colon carcinoma CT26 cell lines [...] Read more.
The synthesis and characterization of biotinylated chlorin photosensitizer and the corresponding zinc and indium complexes are described for potential applications in photodynamic therapy (PDT) for cancer. Phototoxicity of the biotin-chlorin conjugate and the metallated complexes was determined in colon carcinoma CT26 cell lines known to overexpress biotin (Vit B7) receptors. Cell survival assay indicated that the biotinylated chlorin and indium complex showed increased cell growth inhibition than the zinc complex and the starting chlorin (methyl pheophorbide). Fluorescence microcopy studies revealed the generation of apoptotic cells upon light irradiation of colon cells treated with the indium complex. Targeting biotin receptors in cancer cells can improve specificity of photosensitizers for PDT applications. Full article
(This article belongs to the Special Issue Metal-Based Drugs)
Show Figures

Figure 1

Back to TopTop